Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis
Open Access
- 1 July 2015
- journal article
- research article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 109 (7), 914-922
- https://doi.org/10.1016/j.rmed.2015.04.008
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important differenceThorax, 2009
- Small changes in six-minute walk distance are important in diffuse parenchymal lung diseaseRespiratory Medicine, 2009
- Creation of a Model Comparing 6-Minute Walk Test to Metabolic Equivalent in Evaluating Treatment Effects in Pulmonary Arterial HypertensionThe Journal of Heart and Lung Transplantation, 2007
- British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survivalThorax, 2007
- Six-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2005
- The St George's Respiratory QuestionnaireRespiratory Medicine, 1991
- Six minute walking test for assessing exercise capacity in chronic heart failure.BMJ, 1986